Managers

Frequency Therapeutics scores $62 mln Series C

Woburn, Massachusetts-based Frequency Therapeutics, a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has raised $62 million in Series C financing. Perceptive Advisors led the round.

Freenome nabs $160 mln Series B

South San Francisco-based Freenome, a provider of a multiomics platform for early cancer detection through a routine blood draw, has secured $160 million in Series B financing. RA Capital Management and Polaris Partners led the round.

TScan Therapeutics snags over $48 mln Series B

TScan Therapeutics, which designs therapies that reprogram a patient’s own T cells, has raised over $48 million in Series B financing. TScan's backers included Bessemer Venture Partners, Google Ventures, Longwood Fund and Novartis Venture Fund.

Longtime entrepreneur and investor Goldstein joins Builders VC

X-Vax rakes in $56 mln

Jupiter, Florida-based X-Vax Technology Inc, a herpes vaccines developer, has raised $56 million in funding. The investors included Johnson & Johnson Innovation – JJDC, Inc., Adjuvant Capital, Serum Institute of India, Alexandria Venture Investments and FF DSF VI.</strong

Flare Capital raises $255 mln for sophomore fund

Flare Capital Partners has closed its second fund at $255 million. The Boston-based venture firm invests in healthcare technology.

Seed investors top list of most active VCs in Q2

NewView leads $55 mln deal with Heap

ACME Capital, formerly Sherpa, to raise $200 mln fund

Newly launched Sony, Daiwa fund will not take U.S. LP money ... for now